These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 15668276)

  • 21. High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients.
    Kong Y; Dai S; Xie X; Xiao X; Lv N; Guo J; Li L; Jia W; Zhang Y; Liu W; Wei W; Xie X
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):275-84. PubMed ID: 22116318
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.
    Kim JW; Kim JH; Im SA; Kim YJ; Han HS; Kim JS; Lee KH; Kim TY; Han SW; Jeon YK; Oh DY; Kim TY; Park IA
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):109-15. PubMed ID: 23673443
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer.
    Kogawa T; Fouad TM; Liu DD; Wu J; Shen Y; Masuda H; Fujii T; Chavez-MacGregor M; Alvarez RH; Hortobágyi GN; Valero V; Ueno NT
    Oncologist; 2016 Jan; 21(1):21-7. PubMed ID: 26659222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Weekly paclitaxel plus carboplatin with or without trastuzumab as neoadjuvant chemotherapy for HER2-positive breast cancer: loss of HER2 amplification and its impact on response and prognosis.
    Wang RX; Chen S; Jin X; Chen CM; Shao ZM
    Breast Cancer Res Treat; 2017 Jan; 161(2):259-267. PubMed ID: 27885439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of trastuzumab to chemotherapy produces 50% increase in survival in patients selected by FISH.
    Oncology (Williston Park); 2001 Oct; 15(10):1345, 1364. PubMed ID: 11702961
    [No Abstract]   [Full Text] [Related]  

  • 27. Lower response to trastuzumab emtansine in metastatic breast cancer patients with human epidermal growth factor receptor 2 immunohistochemistry score of 2 and fluorescence in situ hybridization positive compared with immunohistochemistry score of 3: a retrospective study.
    Yazaki S; Hashimoto J; Ogita S; Nakano E; Suzuki K; Yamauchi T
    Anticancer Drugs; 2020 Oct; 31(9):973-978. PubMed ID: 32868644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab.
    Gori S; Sidoni A; Colozza M; Ferri I; Mameli MG; Fenocchio D; Stocchi L; Foglietta J; Ludovini V; Minenza E; De Angelis V; Crinò L
    Ann Oncol; 2009 Apr; 20(4):648-54. PubMed ID: 19188134
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study.
    Burstein HJ; Harris LN; Gelman R; Lester SC; Nunes RA; Kaelin CM; Parker LM; Ellisen LW; Kuter I; Gadd MA; Christian RL; Kennedy PR; Borges VF; Bunnell CA; Younger J; Smith BL; Winer EP
    J Clin Oncol; 2003 Jan; 21(1):46-53. PubMed ID: 12506169
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial.
    Hurvitz SA; Andre F; Jiang Z; Shao Z; Mano MS; Neciosup SP; Tseng LM; Zhang Q; Shen K; Liu D; Dreosti LM; Burris HA; Toi M; Buyse ME; Cabaribere D; Lindsay MA; Rao S; Pacaud LB; Taran T; Slamon D
    Lancet Oncol; 2015 Jul; 16(7):816-29. PubMed ID: 26092818
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.
    Pierga JY; Delaloge S; Espié M; Brain E; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Spielmann M; Savignoni A; Marty M
    Breast Cancer Res Treat; 2010 Jul; 122(2):429-37. PubMed ID: 20480225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer.
    Zhao J; Krishnamurti U; Zhang C; Meisel J; Wei Z; Suo A; Aneja R; Li Z; Li X
    Pathol Res Pract; 2020 Nov; 216(11):153155. PubMed ID: 32871536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
    Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
    Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A retrospective analysis of trastuzumab-based therapy in metastatic breast cancer patients at Masaryk Memorial Cancer Institute. Identification of predictive factors].
    Svoboda M; Grell P; Simícková M; Fabian P; Petráková K; Palácová M; Macková D; Trojanec R; Hajdúch M; Pavlík T; Nenutil R; Vyzula R
    Klin Onkol; 2008; 21(6):348-58. PubMed ID: 19382598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy.
    Mazouni C; Hall A; Broglio K; Fritsche H; Andre F; Esteva FJ; Hortobagyi GN; Buzdar AU; Pusztai L; Cristofanilli M
    Cancer; 2007 Feb; 109(3):496-501. PubMed ID: 17149760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER2 testing in a population-based study of patients with metastatic breast cancer treated with trastuzumab.
    O'Malley FP; Thomson T; Julian J; Have C; Cosby R; Gelmon K; Andrulis I; Whelan T
    Arch Pathol Lab Med; 2008 Jan; 132(1):61-5. PubMed ID: 18181675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
    Müller V; Witzel I; Lück HJ; Köhler G; von Minckwitz G; Möbus V; Sattler D; Wilczak W; Löning T; Jänicke F; Pantel K; Thomssen C
    Breast Cancer Res Treat; 2004 Jul; 86(1):9-18. PubMed ID: 15218357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.
    Pegram MD; Pienkowski T; Northfelt DW; Eiermann W; Patel R; Fumoleau P; Quan E; Crown J; Toppmeyer D; Smylie M; Riva A; Blitz S; Press MF; Reese D; Lindsay MA; Slamon DJ
    J Natl Cancer Inst; 2004 May; 96(10):759-69. PubMed ID: 15150304
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pathological complete response and prognosis in patients receiving neoadjuvant paclitaxel and trastuzumab with and without anthracyclines for stage II and III, HER2-positive operable breast cancer: a single-institute experience.
    Horiguchi J; Oyama T; Takata D; Rokutanda N; Nagaoka R; Odawara H; Tokiniwa H; Tozuka K; Kikuchi M; Sato A; Takeyoshi I
    Anticancer Res; 2011 Sep; 31(9):3041-6. PubMed ID: 21868556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.
    Burstein HJ; Lieberman G; Slamon DJ; Winer EP; Klein P
    Ann Oncol; 2005 Nov; 16(11):1772-7. PubMed ID: 16150805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.